nach oben

Erschienen in:

01.10.2014 | Review

Recommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT)

verfasst von: R. Bruno, G. Carosi, N. Coppola, G. B. Gaeta, M. Puoti, T. Santantonio, G. Taliani, O. Armignacco, E. Sagnelli, M. Andreoni, G. Angarano, G. Di Perri, G. D’Offizi, M. Galli, G. Rizzardini

Erschienen in: Infection | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To develop recommendations for the management of acute hepatitis B by the Italian Society for the Study of Infectious and Tropical Diseases.

Methods

Development of the recommendations divided into three levels of evidence according to the GRADE system: A (high), B (medium) and C (low experts opinion), together with three recommendation levels: 1 (strong), 2 (medium), 3 (weak).

Results

The treatment with antivirals is in selected cases the mainstay of management of severe acute hepatitis, and should be started as a matter of urgency in order to prevent death.

Conclusions

These recommendations are meant to provide the rationale and practical indications for the management of acute hepatitis B (AHB).

Kumar M, Satapathy S, Monga R, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology. 2007;45:96–101.CrossRef

Yu JW, Sun LJ, Zhao YH, et al. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci. 2010;56:775–83.CrossRef

Tillmann HL, Hadem J, Leifeld L, Zachou K, Canby A, Eisenbach C, et al. Safety and efficacy of lamivudine in patients with severe acute fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006;13:256–63.

European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.

Ito K, Yotsuyanagi H, Yatsuhashi H, Karino Y, Takikawa Y, Saito T, Arase Y, Imazeki F, Kurosaki M, Umemura T, Ichida T, Toyoda H, Yoneda M, Mita E, Yamamoto K, Michitaka K, Maeshiro T, Tanuma J, Tanaka Y, Sugiyama M, Murata K, Masaki N, Mizokami M; Japanese AHB Study Group. Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. Hepatology. 2014;59(1):89–97. doi:10.1002/hep.26635.

Chulanov VP, Shipulin GA, Schaefer S, Gerlich WH. Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without coinfection by other hepatitis viruses. J Med Virol. 2003;69:313–23.PubMedCrossRef

Baxa DM, Thekdi AD, Golembieski A, Krishnan PV, Sharif O, Kizy A, Shetron-Rama L, Jovanovich J, Chappell BJ, Snow-Lampart A, Borroto-Esoda K, Gordon SC. Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States. J Hepatol. 2013;58:212–6.PubMedCrossRef

Coppola N, Tonziello G, Colombatto P, Pisaturo M, Messina V, Moriconi F, Alessio L, Sagnelli C, Cavallone D, Brunetto M, Sagnelli E. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. J Infect. 2013;67:322–8.PubMedCrossRef

European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–42.CrossRef

10.

Tillmann HL, Zachou K, Dalekos GN. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? Liver Int. 2012;32:544–53.PubMedCrossRef

11.

Rapicetta M, Ferrari C, Levrero M. Viral determinants and host immune responses in the pathogenesis of HBV infection. J Med Virol. 2002;67:454–7.PubMedCrossRef

12.

Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improve the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology. 2011;53:774–80.PubMedCrossRef

13.

Galli M, Crocchiolo P, Negri C, et al. Attempt to treat acute type B hepatitis with an orally administered thymic extract (thymomodulin): preliminary results. Drugs Exp Clin Res. 1985;11:665–9.PubMed

14.

Galský J, Bansky G, Holubová T, Kõnig J. Effect of ursodeoxycholic acid in acute viral hepatitis. J Clin Gastroenterol 1999;28:249–53.

15.

Fabris P, Tositti G, Mazzella G, Zanetti AR, Nicolin R, Pellizzer G, Benedetti P, de Lalla F. Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study. Aliment Pharmacol Ther. 1999;13:1187–93.

16.

Weiss L, Hildt E, Hofschneider PH. Anti-hepatitis B virus activity of N-acetyl-l-cysteine (NAC): new aspects of a well-established drug. Antivir Res. 1996;32:43–53.PubMedCrossRef

17.

Gunduz H, Karabay O, Tamer A, et al. N-acetyl cysteine therapy in acute viral hepatitis. World J Gastroenterol. 2003;9:2698–700.PubMed

18.

Evans TW. Review article: albumin as a drug—biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther. 2002;16:6–11.PubMedCrossRef

19.

Laleman W, Wilmer A, Evenepoel P, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006;10(4):R108.

20.

Schmidt LE, Wang LP, Hansen BA, et al. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl. 2003;9:290–7.PubMedCrossRef

21.

Saliba F, Camus C, Durand F, et al. Randomized controlled multicentre trial evaluating the efficacy and safety of albumin dialysis with MARS in patients with fulminant and subfulminant hepatic failure. Hepatology 2008;48:LB1.

Titel: Recommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT)
verfasst von: R. Bruno
G. Carosi
N. Coppola
G. B. Gaeta
M. Puoti
T. Santantonio
G. Taliani
O. Armignacco
E. Sagnelli
M. Andreoni
G. Angarano
G. Di Perri
G. D’Offizi
M. Galli
G. Rizzardini
Publikationsdatum: 01.10.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Infection / Ausgabe 5/2014
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI: https://doi.org/10.1007/s15010-014-0642-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Recommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT)

Abstract

Purpose

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2014

Listeria monocytogenes meningoencephalitis in adults: analysis of factors related to unfavourable outcome

The role of colonization pressure in the dissemination of colistin or tigecycline resistant KPC-producing Klebsiella pneumoniae in critically ill patients

Clinical course and quality of care in ART-naïve patients newly presenting in a HIV outpatient clinic

A novel case of chronic conjunctivitis in a 58-year-old woman caused by Raoultella

Intensive care unit-acquired blood stream infections: a 5-year retrospective analysis of a single tertiary care hospital in Korea

Erratum to: Oxacillin-susceptible methicillin-resistant Staphylococcus aureus (OS-MRSA), a hidden resistant mechanism among clinically significant isolates in the Wessex region/UK

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin